FIP YPG Webinar Report

Introduction to FIP Special Interest Groups: Drug Delivery and Manufacturing, New Medicines, and New Generation of Pharmaceutical Scientists.

This report was prepared by:
Mercy Kamya, FIP YPG Professional Development Team member
Juliet Obi, FIP YPG Liaison to the New Medicines SIG
1. **Webinar title**

   Introduction to FIP Special Interest Groups: Drug Delivery and Manufacturing, New Medicines, and New Generation of Pharmaceutical Scientists.

2. **Webinar date and time**

   The webinar was held on 12th July 2020 between 3:00 PM and 4:00 PM GMT.

3. **Background**

   The engagement and involvement of young pharmacists and pharmaceutical scientists is important to facilitate the transitioning of FIP YPG members to the FIP Special Interest Groups (SIGs). This engagement and involvement can be achieved by providing information on the activities and opportunities within the SIGs. Through this webinar, we aimed to increase the awareness of FIP YPG members on the SIGs' structures, leadership, and their activities. This webinar was focused on FIP's SIGs on Drug Delivery and Manufacturing (DDM), New Medicines, and New Generation of Pharmaceutical Scientists (NGPS).

4. **Webinar’s learning outcomes**

   The learning objectives of this webinar were to:

   a. Outline the history and objectives of the SIGs on DDM, New Medicines, and NGPS,
   b. Outline the different activities carried out by the SIGs, and any opportunities available within the SIGs, and
   c. Show how interested members can get involved with the SIGs.

5. **Registration and attendance**

   There were 380 registrants to this webinar, with an attendance rate of 38% (146 attendees). The top five countries were Philippines, Nigeria, Indonesia, India and Pakistan.

6. **Speaker highlights**

   a. Juliet Obi (Graduate Student, University of Maryland, Baltimore; FIP YPG Liaison to New Medicines SIG)

      The webinar started with an introduction by the moderator, Juliet Obi. She introduced the webinar topic to the attendees, including the overview of the webinar, and the learning outcomes the attendees should expect at the end of the webinar. She then moved on to
introducing each of the speakers by reading their biography. Each of the speakers below gave a brief presentation by introducing their respective SIGs, and highlighting the activities they carry out, and opportunities available within their SIG.

b. Prof Aliasger Salem (Vice Chair of SIG Drug Design and Manufacturing, College of Pharmacy, University of Iowa)
Prof. Salem began his presentation by giving a brief scope and the goal of the DDM SIG. The DDM SIG aims to provide a dynamic international forum for the exchange of knowledge among FIP members who share a common interest in the design, manufacturing, and testing of drug delivery systems. The major focus areas for the DDM SIG include, but are not limited to pharmaceutical analysis and compounding, manufacturing sciences, biopharmaceutics, molecular pharmaceutics, and advanced drug delivery systems including nanotechnology, 3D printing, digital health, amongst others. The DDM SIG is chaired by Professor Tetsuya Ozeki, a professor at Nagoya City University, Japan. Vice chairs include Erem Bilensoy from Hacettepe University, Turkey and Prof. Aliasger Salem from the University of Iowa School of Pharmacy. Prof. Salem ended his presentation by highlighting some recent developments in the pharmaceutical sciences including tissue regeneration, gene editing, 3D printing, nanomedicine, and cancer immunotherapy.

c. Prof Takuya Kumamoto (Department of Synthetic Organic Chemistry, Hiroshima University, FIP Chair SIG New Medicines)
Prof. Takuya began his presentation by highlighting FIP’s role in bringing together science, education, and practice. He then gave a brief overview of the early stages of drug discovery and provided the scope of the New Medicines SIG. The New Medicines SIG provides a platform for the discussion of a wide range of research topics in the pharmaceutical sciences related to drug discovery and development. This includes research areas in medicinal chemistry, natural medicines, pharmacology, biologics, and cell and gene therapies. The New Medicines SIG is a part of the newly formed SIGs after FIP BPS underwent some restructuring in 2019. The New Medicines SIG is chaired by Prof. Takuya Kumamoto. There is currently no Vice Chair for the SIG. The SIG is also divided into various focus groups including small molecules, biologics, pharmacology, cell and gene therapies, and natural products and traditional medicines. The activities carried out
within the SIG were also highlighted, which mainly include organising sessions at FIP World Congresses and the PSWC, in collaboration with other SIGs, Board of Pharmaceutical Practice (BPP) Sections, and YPG. Prof. Takuya then briefly presented a short story on recent progress in drug discovery, by talking about the drug design of Remdesivir, the antiviral drug which was recently repurposed for the treatment of SARS-CoV-2. Prof. Takuya ended his presentation by talking about the focus groups of the SIG, and a brief presentation on the goals of each focus group with appointed chairs.

d. Dr. Rebecka Isaksson (Postdoctoral Research Associate, Chair New Generation of Pharmaceutical Sciences SIG, University of Edinburgh)

Dr. Rebecka Isaksson began her presentation by providing an overview and brief history of the NGPS SIG. The NGPS SIG began in 2017, during the 1st Young Scientist Conference in Uppsala, Sweden. Dr. Rebecka became chair of this SIG in 2018, and then the SIG restructuring in 2019 led to the inclusion of the NGPS SIG as one of the SIGs under FIP’s Board of Pharmaceutical Sciences (BPS). The leadership team for the NGPS SIG was also selected in 2019. The NGPS SIG aims to stimulate communication, networking and collaboration with other FIP and non-FIP groups of young professionals. It also aims to enable effective outreach activities to pharmaceutical science communities within the formative years. Dr. Rebecka ended her presentation by highlighting some opportunities and upcoming activities to be carried out by the SIG including a webinar on career pathways for pharmaceutical scientists, which will be launched in October 2020. She also mentioned the collaboration between YPG and NGPS on a project aimed at mapping soft skills for young pharmacists and pharmaceutical scientists.

7. Conclusion

The webinar ended with a Question and Answer session moderated by Juliet Obi, after which she wrapped up with concluding remarks and formally ended the webinar. The recording of the webinar can be accessed by FIP members through this link: https://bit.ly/32GaSuQ
8. Acknowledgements

This webinar was organised by FIP YPG through a collaboration between Clement Haeck (FIP YPG DDM SIG Liaison), Nicole Savant (FIP YPG NGPS Liaison), and Juliet Obi (FIP YPG New medicines Liaison). Mercy Kamya (FIP YPG Professional Development Team member) led the planning of the webinar together with Ayodeji Matuluko (FIP YPG Chairperson of Projects 2020). The webinar organisers would like to acknowledge the FIP YPG media team who promoted this event on all of FIP YPG’s social media channels, Dr. Renly Lim (FIP YPG President-elect) for her input in the initial structuring of the webinar and Sherly Meilianti (FIP YPG President) for her input in this FIP YPG webinar report.